Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
March 09 2022 - 7:00AM
Business Wire
Twist Bioscience Corporation
(NASDAQ: TWST), a company enabling customers to succeed through its
offering of high-quality synthetic DNA using its silicon platform,
and Kriya Therapeutics, Inc., a fully
integrated company pioneering novel technologies and therapeutics
in gene therapy, today announced an antibody discovery agreement
for antibodies delivered using adeno-associated viral (AAV) gene
therapy in therapeutic oncology applications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220309005115/en/
“We believe that vectorized antibodies have the potential to
transform the treatment of a range of serious diseases,
particularly within the field of oncology,” said Shankar Ramaswamy,
M.D., Co-Founder and Chief Executive Officer of Kriya. “By
combining Twist’s best-in-class antibody libraries and discovery
expertise with Kriya’s proprietary, computationally-enabled vector
engineering platform, we can accelerate the advancement of novel
gene therapies that can be combined with other modalities in
oncology, including current standards-of-care.”
Twist Biopharma, a division of Twist Bioscience, expects to
leverage its antibody discovery and optimization platform to
discover novel antibodies against specific targets of interest that
will be engineered into Kriya’s proprietary gene therapy technology
platform for durable and targeted delivery.
“Targeted delivery of antibodies using gene therapy could open a
new therapeutic channel that enables precise treatment where needed
locally,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Twist Bioscience. “Viral vectors provide an expedited route to
deliver much needed proteins to patients over traditional biologics
development. Kriya’s AAV technology is world-leading so we are very
pleased to partner with them in this field.”
About Kriya Therapeutics
Kriya is a fully integrated company pioneering novel
technologies and therapeutics in gene therapy. The company aims to
revolutionize how gene therapies are designed, developed, and
manufactured, improving speed to market and delivering significant
reductions in cost. Kriya is organized into four principal business
units: Kriya Technologies™, Kriya Therapeutics™, Kriya R&D™,
and Kriya Manufacturing™. The company is advancing a deep and
diversified pipeline of innovative gene therapies in multiple
therapeutic area divisions, with current pipeline programs in
ophthalmology, oncology, rare disease, and chronic disease. Kriya
was founded by pioneers in the biopharmaceutical industry and is
backed by leading life sciences and technology investors. The
company has core operations in Silicon Valley, California and
Research Triangle Park, North Carolina. For more information,
please visit www.kriyatx.com and
follow on LinkedIn.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn |
YouTube
About Twist Biopharma
By leveraging our unique ability to manufacture DNA at scale, we
can construct proprietary antibody libraries precisely designed to
match sequences that occur in the human body. This library of
libraries gives our partners an integral and unbiased resource for
antibody therapeutic discovery and optimization. This precise and
rational approach to library fabrication combined with
sophisticated bioinformatics and software expertise expedites
antibody discovery by decreasing risk, increasing speed, and
lowering the failure rate for antibody therapeutic development.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability of Twist Biopharma to
leverage its antibody discovery and optimization platform to
discover novel antibodies and the ability of Kriya Therapeutics to
achieve milestones or develop any products under the agreement. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q
filed with the Securities and Exchange Commission on February 9,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220309005115/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925- 202-6211 abitting@twistbioscience.com
Kriya Danielle Cantey Canale
Communications for Kriya danielle.cantey@canalecomm.com (619)
826-4657
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024